Propranolol for treatment of ulcerated infantile hemangiomas.
J Am Acad Dermatol
; 64(5): 827-32, 2011 May.
Article
em En
| MEDLINE
| ID: mdl-21353332
ABSTRACT
BACKGROUND:
Ulcerated infantile hemangiomas (IH) are a therapeutic challenge. Propranolol, a nonselective beta-blocker, was recently introduced as a novel treatment for IH.OBJECTIVE:
To evaluate our experience of propranolol in the management of ulcerated IH.METHODS:
A national, multicenter, retrospective, observational study was conducted. Data were collected from the medical charts of patients treated from 2008 to 2009 and supplemented by information obtained from parents during targeted telephone interviews.RESULTS:
Thirty-three infants with propranolol-treated ulcerated IH were included. The average time to complete ulceration healing was 4.3 weeks in 30 of 33 patients and was significantly faster for head-and-neck locations (P = .0354). The mean time to complete pain control was 14.5 days. Parents rated treatment as very effective for 27 of 31 patients and very well tolerated for 29 of 31 cases.LIMITATIONS:
This was a retrospective uncontrolled study.CONCLUSION:
Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Propranolol
/
Neoplasias Cutâneas
/
Antagonistas Adrenérgicos beta
/
Hemangioma
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article